文献速递血栓与止血

复发性静脉血栓栓塞长期风险:REVERSE队列研究

Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study.
PubMed 文献 · J Thromb Haemost · 2021-04-21

REVERSE队列研究评估首次静脉血栓栓塞(VTE)时使用复方口服避孕药(COC)女性的长期复发风险。COC使用者复发率1.1%/患者年(95%CI 0.3-2.9),非使用者3.2%/患者年(95%CI 2.4-4.3),风险比0.37(95%CI 0.1-1.0)。HERDOO2评分高风险亚组中,COC使用者复发率3.5%(95%CI 0.4-12.5),非使用者6.1%(95%CI 4.3-8.5),HR 0.6(95%CI 0.1-2.5)。

要点

  • 首次VTE时使用COC的女性长期复发风险低于非使用者。
  • HERDOO2评分可帮助识别COC使用者的高风险亚组。
  • COC使用者高风险亚组复发率3.5%/患者年,非使用者6.1%/患者年。

核心结论

  • 首次无诱因VTE时使用COC的女性,长期随访中VTE复发率低于非使用者。

研究设计与样本

  • REVERSE队列研究,比较COC使用与非使用女性首次VTE后的复发风险,并分析HERDOO2亚组。

主要发现

  • COC使用者复发率1.1%/患者年(95%CI 0.3-2.9),非使用者3.2%/患者年(95%CI 2.4-4.3),HR 0.37(95%CI 0.1-1.0)。
  • COC使用者且HERDOO2高风险者复发率3.5%(95%CI 0.4-12.5),非COC使用者且高风险者6.1%(95%CI 4.3-8.5),HR 0.6(95%CI 0.1-2.5)。

关键数值与推荐

  • HERDOO2高风险定义包括:下肢色素沉着、水肿或发红;D-二聚体≥250 μg/L;肥胖(BMI≥30);年龄≥65岁。

临床怎么用

  • 对首次VTE时使用COC的女性,可参考HERDOO2评分评估长期复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The risk of recurrent venous thromboembolism (VTE) after combined oral contraceptive (COC) use is variably reported. We assessed the long-term risk of recurrent VTE in women on COC at the time of a first VTE, in comparison to women without COC use. Our secondary aim assessed the impact of COC use on the recurrent VTE risk in high-risk and low-risk hyperpigmentation, edema, or redness in either leg; D-dimer level ≥250 μg/L; obesity with body mass index ≥30; or older age, ≥65 years (HERDOO2) subgroups. METHODS: The REVERSE cohort study derived the HERDOO2 clinical decision rule to predict recurrent VTE in patients who discontinued anticoagulation after 5-7 months for a first unprovoked VTE. Incidence rates of recurrent VTE among women with and without COC exposure were calculated as the number of recurrent VTE over the number of person-years of follow-up, and Cox proportional hazards model was used to compare risks between groups. RESULTS: The risk of recurrent VTE among COC users was 1.1% (95% confidence interval [CI] 0.3-2.9) per patient-year as compared with 3.2% per patient-year (95% CI 2.4-4.3) among nonusers (hazard ratio 0.37; 95% CI 0.1-1.0). Women who were COC users and high risk by HERDOO2 score had a recurrence rate of 3.5% (95% CI 0.4-12.5) compared with 6.1% (95% CI 4.3-8.5) among women who were non-COC users and at high risk by HERDOO2 score (HR 0.6, 95% CI 0.1-2.5). CONCLUSIONS: Women who were COC users at the time of an otherwise unprovoked VTE event had a lower VTE recurrence rate during long-term follow-up, compared with nonusers. The use of HERDOO2 rule may help identify higher risk women with COC use.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Aziz D, Skeith L, Rodger MA, et al. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. J Thromb Haemost. 2021. PMID: 33724705. doi:10.1111/jth.15303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。